AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.2 |
Market Cap | 12.36M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.92 |
PE Ratio (ttm) | -0.07 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.21 |
Volume | 387,340 |
Avg. Volume (20D) | 6,791,393 |
Open | 0.20 |
Previous Close | 0.20 |
Day's Range | 0.20 - 0.21 |
52-Week Range | 0.13 - 2.30 |
Beta | undefined |
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Ph...
Analyst Forecast
According to 3 analyst ratings, the average rating for APTO stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 2335.46% from the latest price.
9 months ago · seekingalpha.com
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
2 years ago · seekingalpha.com
Aptose Biosciences Continues To Drift Without Thesis-Changing DataAptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pav...